IL-23 came under the spotlight during this year’s European Academy of Dermatology and Venereology (EADV) Congress in Madrid, Spain, as the subject of a symposium co-chaired by Profs Reich and Warren, and with the latest data from the guselkumab clinical trial programme, reviewed in two separate articles in the latest addition to EMJ Dermatology.
In this issue
Rate this content's potential impact on patient outcomes
Average rating / 5. Vote count:
No votes so far! Be the first to rate this content.
Latest articles
All articles
12 Mins
4th
April
From Bench to Bedside: Keith Choate
If you look closely at the fundamental discoveries that have changed human health, physician–scientists have been at the center of the great majority.
Rate this content's potential impact on patient outcomes Submit Rating Average rating / 5. Vote count: No votes so far! Be the first to rate this content.

3 Mins
3rd
April
Real-World Use of Bimekizumab Therapy for Difficult-to-Treat Plaque Psoriasis
Discover a new study from a large academic center that supports bimekizumab as an effective treatment for moderate-to-severe plaque psoriasis.
Rate this content's potential impact on patient outcomes Submit Rating Average rating / 5. Vote count: No votes so far! Be the first to rate this content.

7 Mins
26th
March
Malignancy Unmasked: Cutaneous Angiosarcoma Arising From Scald Burn
Angiosarcoma is a rare and aggressive malignant neoplasm that arises from endothelial cells of blood or lymphatic vessels, accounting…
Rate this content's potential impact on patient outcomes Submit Rating Average rating / 5. Vote count: No votes so far! Be the first to rate this content.

5 Mins
4th
March
Unpacking the Skin Microbiome: Richard Gallo
AMJ is delighted to welcome Richard Gallo, Professor and Chair of Dermatology at the University of California San Diego, USA. A leading…
Rate this content's potential impact on patient outcomes Submit Rating Average rating / 5. Vote count: No votes so far! Be the first to rate this content.